MEP1A

Across TCGA pan-cancer cohorts, MEP1A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MEP1A data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MEP1A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MEP1A expression acts as an unfavorable survival marker, although some lineages such as OV and CESC show a favorable association.

DLBC, OV, and CESC are the cancer types where MEP1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
OV	OS	Median	III,IV	1.000	0.310	.038	6	view →
CESC	DFS	Median	III,IV	1.000	0.280	.026	6	view →
LIHC	OS	Median	III,IV	0.198	0.648	.021	6	view →
LUSC	OS	Median	All	0.468	0.765	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MEP1A–DLBC (OS)

Open the DLBC breakdown →